Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

The French National Authority for Health (HAS) published new set of decisions regarding add-on reimbursement of medical devices and medical aids in September

The French National Authority for Health (HAS) published a new set of decisions in relation to add-on reimbursement of medical devices and reimbursement of medical aids that had been released by National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in September:

  • Two decisions for knee and hip prostheses were approved by CNEDiMTS:
    • NEXGEN LPS, total knee prosthesis (application for registration, approved)
    • Insert LONGEVITY, highly crosslinked polyethylene hip implants (request for amendment + renewal of registration, approved)
  • Five applications for registrations for therapeutic shoes were approved:
  • Seventeen decisions for devices of treatment of cardio-vascular diseases were published:
  • Two decisions for coronary stents
    • TITAN OPTIMAX, coronary stent with titanium oxynitride coating (renewal of registration, approved)
    •  XPOSITION S, coronary stent coated with sirolimus (application for registration, rejected due to insufficient expected benefit (AS))
  • Ten decisions were prepared for heart valve replacement procedures
    • Devices for aortic valve replacement
      • EPIC SUPRA, bioprosthetic aortic heart valve (application for registration on the list of health products that are financed for hospitalization in accordance to Article L.165-11 and R.165-49 of the Social Security Code, approved)
      • CROWN PRT, bioprosthetic aortic heart valve (application for registration on the list of health products that are financed for hospitalization in accordance to Article L.165-11 and R.165-49 of the Social Security Code, approved)
      • SOLO SMART,  bioprosthetic aortic heart valve (application for registration on the list of health products that are financed for hospitalization in accordance to Article L.165-11 and R.165-49 of the Social Security Code, approved)
      • EPIC,  bioprosthetic aortic heart valve (application for registration on the list of health products that are financed for hospitalization in accordance to Article L.165-11 and R.165-49 of the Social Security Code, approved)
      • TRIFECTA,  bioprosthetic aortic heart valve (application for registration on the list of health products that are financed for hospitalization in accordance to Article L.165-11 and R.165-49 of the Social Security Code, approved)
      • TRIFECTA GT,  bioprosthetic aortic heart valve (application for registration on the list of health products that are financed for hospitalization in accordance to Article L.165-11 and R.165-49 of the Social Security Code, approved)
    • Devices for mitral valve replacement:
      • EPIC Mitral, bioprosthetic mitral heart valve (application for registration on the list of health products that are financed for hospitalization in accordance to Article L.165-11 and R.165-49 of the Social Security Code, approved)
      • PERICARBON MORE MITRAL, bioprosthetic mitral heart valve (application for registration on the list of health products that are financed for hospitalization in accordance to Article L.165-11 and R.165-49 of the Social Security Code, approved)
    • Devices for pulmonary valve replacement
  • Three decisions for peripheral vascular technologies were obtained from CNEDiMTS:

See full list of decisions here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.